Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have been given an average recommendation of “Moderate Buy” by the seven analysts that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $10.80.

A number of research firms have weighed in on SANA. Citizens Jmp raised Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 price objective on the stock in a research note on Tuesday, March 18th. HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of Sana Biotechnology in a report on Thursday, April 24th. Finally, Jefferies Financial Group initiated coverage on shares of Sana Biotechnology in a research note on Friday, March 14th. They set a “buy” rating and a $7.00 target price on the stock.

Hedge Funds Weigh In On Sana Biotechnology

A number of hedge funds have recently made changes to their positions in the stock. Barclays PLC lifted its stake in Sana Biotechnology by 126.6% during the third quarter. Barclays PLC now owns 318,910 shares of the company’s stock worth $1,325,000 after purchasing an additional 178,179 shares in the last quarter. SG Americas Securities LLC acquired a new position in Sana Biotechnology during the 4th quarter worth about $239,000. Charles Schwab Investment Management Inc. grew its position in Sana Biotechnology by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,056,512 shares of the company’s stock valued at $1,722,000 after acquiring an additional 8,666 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Sana Biotechnology by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 3,193,081 shares of the company’s stock worth $5,206,000 after purchasing an additional 26,601 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Sana Biotechnology by 1,838.3% in the fourth quarter. Renaissance Technologies LLC now owns 319,818 shares of the company’s stock valued at $521,000 after purchasing an additional 303,318 shares during the period. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Price Performance

Shares of NASDAQ SANA opened at $1.81 on Friday. The firm has a 50-day simple moving average of $1.93 and a 200-day simple moving average of $2.49. The stock has a market capitalization of $408.11 million, a price-to-earnings ratio of -1.29 and a beta of 1.75. Sana Biotechnology has a 52 week low of $1.26 and a 52 week high of $9.49.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.02. As a group, equities research analysts expect that Sana Biotechnology will post -1.16 EPS for the current year.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.